Kazia Therapeutics (NASDAQ: KZIA)

Last close As at 22/02/2025

1.32

0.04 (3.13%)

Market capitalisation

22m

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Thematics

thematic

TMT

MediaWatch – What now?

thematic

Industrials

Climate: Creating multi-trillion investment opportunities

thematic

Consumer

ConsumerWatch – Looking for a sign

thematic

Financials

Molten Ventures – executive interviews

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free